Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Gerard Verhoef
Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys, gave an oral presentation at the second Southern African Mountain Conference.

South Africa is neglecting and overlooking the economic potential of Aloe ferox, forfeiting millions in potential revenue from this ‘green gold’. In doing so, the country is denying farmers and communities the chance to prosper from the land’s true bounty and is also undermining its biodiversity.

While South Africa harvests a mere 200 tons of Aloe ferox annually, its global competitors, such as Mexico, churn out a staggering 400 000 tons of Aloe vera, says Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys. He gave an oral presentation titled IKS, the public domain and Biotrade during a session on Mountain People's Livelihoods at the second Southern African Mountain Conference (SAMC2025).

Researchers, policy makers, and practitioners from across Southern Africa and beyond came together from 17 to 20 March at the scenic Champagne Sports Resort in the central Maluti-Drakensberg for SAMC2025 themed ‘Overcoming Boundaries and Barriers’.

The next rooibos

SAMC2025, under the patronage of UNESCO and organised by the University of the Free State (UFS) Afromontane Research Unit (ARU) – in partnership with the African Mountain Research Foundation (AMRF) and the Global Mountain Safeguard Research Programme (GLOMOS) – delved into critical issues around mountain ecosystems, communities, governance, and transboundary cooperation.

Aloe ferox could be the next rooibos, which is successfully using its geographical indications (GI) status to unlock value throughout the biotrade value chain, Dr Verhoef said. Other South African plants that are also an underutilised asset with economic potential for the country, include honeybush, baobab, umsuzwane, rose geranium, imphepho, Cape chamomile, Kalahari melon, mafura, sour plum, and African ginger.

A GI consists of the name of the place of origin. It links a product to a specific geographical area, which indicates the origin of where the product is produced, processed, or prepared.

Overlooking the potential of Aloe ferox, which has been scientifically proven to contain double the amino acids and 20 times more antioxidants than its international cousin, Aloe vera, Dr Verhoef explains, South Africa is not only undermining its biodiversity but also the economy. Aloe ferox is most popularly used for its laxative effect (aloe bitters) and as a topical application to the skin, eyes, and mucous membranes. It is also used for many traditional uses as well as cosmetic purposes.

Time to capitalise

According to him, Aloe ferox remains an underutilised asset, relegated to niche markets and small-scale production due to regulatory constraints and the unwillingness to obtain access and benefit-sharing (ABC) permits needed to navigate obstacles in South Africa as well as Namibia, Botswana, Zimbabwe, and Mozambique.

“This is not just an agricultural oversight; it is a glaring economic misstep. It is high time that South Africa capitalises on its green gold, turning the tables on international competitors and finally giving Aloe ferox the global podium it deserves. This is not just an agricultural oversight; it is a glaring economic misstep.

Aloe ferox could be a flagship in the global wellness market, much like rooibos has become for tea. But until we embrace and promote our indigenous resources with the same vigour as we do foreign ones, our ‘green gold’ will remain just out of reach, a latent promise unfulfilled. It’s high time South Africa capitalise and turn the tables on international competitors, finally giving Aloe ferox the global podium it deserves,” said Dr Verhoef.

The path forward, he explains, requires a radical shift in how we view and value our native species. It demands a coalition of dedicated scientists, legal advisers, and farmers to advocate for more accommodating regulations and stronger market support. The pharmaceutical and cosmetic industries – major users of aloe products – must also be brought into the fold to help recalibrate the scales in favour of Aloe ferox. South Africa’s rich biodiversity is a national treasure, yet our approach to leveraging this wealth remains timid and fragmented.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept